Subjects n | 100 | 67 | 59 | |
Age years | 71.3±11.0 | 70.6±9.2 | 70.1±9.4 | 0.721 |
Males | 87 (87.0) | 63 (95.4) | 58 (96.7) | 0.036 |
Current smokers | 28 (28.0) | 17 (25.7) | 21 (35.4) | 0.663 |
FEV1 post-BD % pred | 60.3±16.6 | 51.4±17.3 | 56.0±16.2 | 0.003 |
BDR | | | | |
ΔFEV1 mL | 93.4±87.1 | 71.4±59.7 | 164.0±150.4 | <0.001 |
ΔFEV1 % | 7.6±6.7 | 6.5±5.0 | 13.6±12.0 | <0.001 |
Reversibility | 22 (22.0) | 10 (14.3) | 32 (45.7) | <0.001 |
CAT score | 18.2±8.2 | 19.4±7.0 | 20.0±8.4 | 0.322 |
Severity of airflow limitation | | | | 0.01 |
Mild | 10 (10.0) | 4 (6.0) | 3 (6.4) | |
Moderate | 64 (64.0) | 29 (43.9) | 39 (64.5) | |
Severe | 22 (22.0) | 24 (34.8) | 15 (25.8) | |
Very severe | 4 (4.0) | 10 (15.1) | 2 (3.2) | |
GOLD 2017 groups | | | | 0.442 |
GOLD A | 9 (9.0) | 3 (4.5) | 6 (9.6) | |
GOLD B | 39 (39.0) | 31 (45.4) | 30 (49.0) | |
GOLD C | 8 (8.0) | 1 (1.5) | 2 (3.2) | |
GOLD D | 44 (44.0) | 32 (48.4) | 22 (37.1) | |
ICS at baseline | 57 (57.0) | 39 (59.1) | 37 (61.2) | 0.884 |
Exacerbations in previous year | | | | |
Moderate exacerbations | 1.7±1.3 | 1.6±1.2 | 1.6±1.5 | 0.922 |
Severe exacerbations | 0.15±0.41 | 0.15±0.55 | 0.11±0.32 | 0.811 |
FeNO at V0 ppb | 12.2±4.5 | 18.6±7.0 | 27.5±20.3 | <0.001 |
Circulating eosinophils at V0# | | | | |
Eosinophil count, cells ×103·µL-1 | 0.22±0.13 | 0.25±0.14 | 0.25±0.19 | 0.479 |
Eosinophil % | 2.8±1.4 | 2.9±1.4 | 3.2±2.1 | 0.329 |
Patients with ≥2% eosinophils | 60 (60.0) | 51 (77.2) | 42 (71.1) | 0.298 |